Pharmacological inhibition of microglial ferroptosis for neuroprotection
A novel drug screening platform targeting microglial ferroptosis to prevent neuronal death in neurodegenerative diseases. Utilizes a disease-relevant model system for drug discovery, aiming to improve therapeutic outcomes for conditions like ALS.
Overview
The University of Melbourne's Microbiology & Immunology Department presents a cutting-edge approach to neuroprotection through the pharmacological inhibition of microglial ferroptosis. This research posits that targeting non-cell autonomous glial mechanisms can prevent neuronal death across various neurodegenerative diseases, including ALS. By focusing on microglial ferroptosis, this solution offers a promising pathway for novel drug development, aiming to provide enhanced therapeutic efficacy in neurodegenerative conditions.
Technical specifications
- Disease-relevant model system: Utilizes a tripartite model where ferroptotic stress is induced in microglia, followed by neurotoxic astrocyte activation, resulting in neuronal death.
- Two-stage drug screening process:
- Stage 1: Utilizes primary cells from mice to screen drug candidates effectively and replicate human disease features.
- Stage 2: Employs iPSC-derived cells from patients to ensure human disease relevance and validate lead candidates.
- Proven efficacy: Demonstrated neuroprotection and extended survival in ALS mouse models through inhibition of microglial ferroptosis.
Technology readiness level
Currently, this technology is at TRL 5, indicating that it has been validated in relevant environments, with ongoing efforts to transition from primary mouse cells to iPSC-derived human cells for enhanced clinical relevance.
About The University of Melbourne
The University of Melbourne is a comprehensive institution spanning STEM, health and clinical practice, business and law, and the creative and social disciplines. Co‑located hospital and research precincts, together with an inner‑city innovation ecosystem, place companies, startups, and researchers in shared labs, prototyping spaces, and studios. Engineering and technology programs connect with advanced manufacturing facilities, while structured industry projects and placements link partners with talent and translational problem‑solving. Work is supported by competitive funding from the Australian Research Council and the National Health and Medical Research Council, with additional backing from state programs and industry partners; a dedicated technology transfer office manages IP, licensing, and startup formation.
delivered to your inbox.